273 related articles for article (PubMed ID: 32786890)
1. Interaction of Drug Candidates with Various SARS-CoV-2 Receptors: An in Silico Study to Combat COVID-19.
Barros RO; Junior FLCC; Pereira WS; Oliveira NMN; Ramos RM
J Proteome Res; 2020 Nov; 19(11):4567-4575. PubMed ID: 32786890
[TBL] [Abstract][Full Text] [Related]
2. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease.
Hall DC; Ji HF
Travel Med Infect Dis; 2020; 35():101646. PubMed ID: 32294562
[TBL] [Abstract][Full Text] [Related]
3. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
4. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
5. COVID-19: Rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main Protease Inhibitor.
Feitosa EL; Júnior FTDSS; Nery Neto JAO; Matos LFL; Moura MHS; Rosales TO; De Freitas GBL
Int J Med Sci; 2020; 17(14):2133-2146. PubMed ID: 32922174
[TBL] [Abstract][Full Text] [Related]
6. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
Vardhan S; Sahoo SK
Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
[TBL] [Abstract][Full Text] [Related]
7.
Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
[TBL] [Abstract][Full Text] [Related]
8. In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins.
Maffucci I; Contini A
J Proteome Res; 2020 Nov; 19(11):4637-4648. PubMed ID: 32893632
[TBL] [Abstract][Full Text] [Related]
9. Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2's main protease.
Huynh T; Wang H; Luan B
Phys Chem Chem Phys; 2020 Nov; 22(43):25335-25343. PubMed ID: 33140777
[TBL] [Abstract][Full Text] [Related]
10. Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease.
Tsuji M
FEBS Open Bio; 2020 Jun; 10(6):995-1004. PubMed ID: 32374074
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.
Anand P; Puranik A; Aravamudan M; Venkatakrishnan AJ; Soundararajan V
Elife; 2020 May; 9():. PubMed ID: 32452762
[TBL] [Abstract][Full Text] [Related]
12. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
13. Protease Inhibitory Effect of Natural Polyphenolic Compounds on SARS-CoV-2: An In Silico Study.
Singh R; Gautam A; Chandel S; Ghosh A; Dey D; Roy S; Ravichandiran V; Ghosh D
Molecules; 2020 Oct; 25(20):. PubMed ID: 33050360
[TBL] [Abstract][Full Text] [Related]
14. Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs.
Calligari P; Bobone S; Ricci G; Bocedi A
Viruses; 2020 Apr; 12(4):. PubMed ID: 32295237
[TBL] [Abstract][Full Text] [Related]
15. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
16. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds.
Ton AT; Gentile F; Hsing M; Ban F; Cherkasov A
Mol Inform; 2020 Aug; 39(8):e2000028. PubMed ID: 32162456
[TBL] [Abstract][Full Text] [Related]
17. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
Martorana A; Gentile C; Lauria A
Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
[TBL] [Abstract][Full Text] [Related]
18. Coronavirus disease 2019 drug discovery through molecular docking.
Singh S; Florez H
F1000Res; 2020; 9():502. PubMed ID: 32704354
[No Abstract] [Full Text] [Related]
19. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
[TBL] [Abstract][Full Text] [Related]
20. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
